Tennessee Retina is an active participant in many national research trials. The efforts of our physicians and patients have led to the approval of many treatments now considered to be the standard of care, and our continuing involvement in clinical research offers access to new and potentially superior treatments to patients with sight-threatening conditions.

As with all patients, our clinical trial patients are very important to us, and we provide them with exceptional care and attention. Please contact your current eyecare provider to see if you may qualify for one of our studies, or contact one of our Clinical Trial staff members with any questions at (615) 983-6000.

Diabetes in the Eyes

INSIGHT (Enrolling)
NCT03610646  Clinical
A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema

RHINE GR40398 (Enrolling)
NCT03622593  Clinical
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients With Diabetic Macular Edema

AERPIO (Active, Enrollment Closed)
NCT03197870  Clinical
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy

PANORAMA (Active, Enrollment Closed)
NCT02718326  Clinical
A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy


Age-Related Macular Degeration (AMD)

PAN OPTICA (Enrolling)
NCT03479372  Clinical
A Randomized, Double Masked, Uncontrolled , Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants With Neovascular Age-Related Macular Degeneration

ADVM-022-01 (Enrolling)
NCT03748784  Clinical
An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration

ASTELLAS (Enrolling)
NCT03178149  Clinical
A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration

ARCHWAY - GR40548 (Active, Enrollment Closed)
NCT03677934  Clinical
Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

LADDER (Active, Enrollment Closed)
NCT02510794  Clinical
A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

TRISTAR (Active, Enrollment Closed)
NCT03468296  Clinical
Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

PORTAL - LADDER EXT GR40549 (Active, Enrollment Closed)
NCT03683251  Clinical
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

GR39821 (Active, Enrollment Closed)
NCT03295877  Clinical
A Phase I, Multicenter, Open-Label, Single-Dose, Dose-Escalation, and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7171009 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration


Vein Occlusion

SCORE 2 (Active, Enrollment Closed)
NCT01969708  Clinical
Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.

"I so appreciate this entire team - I've seen Drs Wallace and Schneider - couldn't have had better care for my retinal detachment. As a nurse, I love that I am asked to confirm my DOB with each encounter. It is clear this has been hard-wired into your workflow. Everyone is friendly and professional."

via Facebook